 | • レポートコード：MRC2304L245 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、222ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療機器 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に106.7億ドルであった世界のうっ血性心不全（CHF）治療装置市場規模が、2022年に115.1億ドルへと拡大し、その後CAGR 8.05％で成長して2027年までに169.9億ドルに達すると予測しています。当書は、うっ血性心不全（CHF）治療装置の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別（心臓再同期療法、植込み型除細動器、ペースメーカー、心室補助装置）分析、エンドユーザー別（外来手術センター、病院＆クリニック）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめています。なお、当書に掲載されている企業情報には、Abiomed, Inc.、Berlin Heart GmbH、Biotronik SE & Co. KG、Boston Scientific Corporation、HeartWare International, Inc.、Jarvik Heart, Inc.、LivaNova PLC、Medtronic plc、ReliantHeart Inc.、St. Jude Medical, Inc.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のうっ血性心不全（CHF）治療装置市場規模：製品別 - 心臓再同期療法の市場規模 - 植込み型除細動器の市場規模 - ペースメーカーの市場規模 - 心室補助装置の市場規模 ・世界のうっ血性心不全（CHF）治療装置市場規模：エンドユーザー別 - 外来手術センターにおける市場規模 - 病院＆クリニックにおける市場規模 ・世界のうっ血性心不全（CHF）治療装置市場規模：地域別 - 南北アメリカのうっ血性心不全（CHF）治療装置市場規模 アメリカのうっ血性心不全（CHF）治療装置市場規模 カナダのうっ血性心不全（CHF）治療装置市場規模 ブラジルのうっ血性心不全（CHF）治療装置市場規模 ... - アジア太平洋のうっ血性心不全（CHF）治療装置市場規模 日本のうっ血性心不全（CHF）治療装置市場規模 中国のうっ血性心不全（CHF）治療装置市場規模 インドのうっ血性心不全（CHF）治療装置市場規模 韓国のうっ血性心不全（CHF）治療装置市場規模 台湾のうっ血性心不全（CHF）治療装置市場規模 ... - ヨーロッパ/中東/アフリカのうっ血性心不全（CHF）治療装置市場規模 イギリスのうっ血性心不全（CHF）治療装置市場規模 ドイツのうっ血性心不全（CHF）治療装置市場規模 フランスのうっ血性心不全（CHF）治療装置市場規模 ロシアのうっ血性心不全（CHF）治療装置市場規模 ... - その他地域のうっ血性心不全（CHF）治療装置市場規模 ・競争状況 ・企業情報 |
The Global Congestive Heart Failure Treatment Device Market size was estimated at USD 10.67 billion in 2021 and expected to reach USD 11.51 billion in 2022, and is projected to grow at a CAGR 8.05% to reach USD 16.99 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Congestive Heart Failure Treatment Device to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Cardiac Resynchronization Therapy, Implantable Cardioverter Defibrillator, Pacemaker, and Ventricular Assist Device. The Cardiac Resynchronization Therapy is further studied across Cardiac Resynchronization Therapy-Defibrillator and Cardiac Resynchronization Therapy-Pacemaker. The Implantable Cardioverter Defibrillator is further studied across Subcutaneous Implantable Cardioverter Defibrillator and Transvenous Implantable Cardioverter Defibrillator. The Ventricular Assist Device is further studied across Biventricular Assist Device, Left Ventricular Assist Device, and Right Ventricular Assist Device.
Based on End-User, the market was studied across Ambulatory Surgery Center and Hospitals & Clinics.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Congestive Heart Failure Treatment Device market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Congestive Heart Failure Treatment Device Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Congestive Heart Failure Treatment Device Market, including Abiomed, Inc., Berlin Heart GmbH, Biotronik SE & Co. KG, Boston Scientific Corporation, HeartWare International, Inc., Jarvik Heart, Inc., LivaNova PLC, Medtronic plc, ReliantHeart Inc., and St. Jude Medical, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Congestive Heart Failure Treatment Device Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Congestive Heart Failure Treatment Device Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Congestive Heart Failure Treatment Device Market?
4. What is the competitive strategic window for opportunities in the Global Congestive Heart Failure Treatment Device Market?
5. What are the technology trends and regulatory frameworks in the Global Congestive Heart Failure Treatment Device Market?
6. What is the market share of the leading vendors in the Global Congestive Heart Failure Treatment Device Market?
7. What modes and strategic moves are considered suitable for entering the Global Congestive Heart Failure Treatment Device Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing susceptibility to heart failure and arrhythmia owing to changing lifestyles
5.1.1.2. Increasing focus on early and primary intervention of heart-related disorders
5.1.1.3. Surge in geriatric population globally
5.1.2. Restraints
5.1.2.1. Relatively expensive devices and preference for drugs
5.1.3. Opportunities
5.1.3.1. Emerging adoption rate of these devices globally
5.1.3.2. Technological advancements in CHF treatment devices
5.1.4. Challenges
5.1.4.1. Stringent regulatory approval process
5.2. Cumulative Impact of COVID-19
6. Congestive Heart Failure Treatment Device Market, by Product
6.1. Introduction
6.2. Cardiac Resynchronization Therapy
6.3.1. Cardiac Resynchronization Therapy-Defibrillator
6.3.2. Cardiac Resynchronization Therapy-Pacemaker
6.3. Implantable Cardioverter Defibrillator
6.4.1. Subcutaneous Implantable Cardioverter Defibrillator
6.4.2. Transvenous Implantable Cardioverter Defibrillator
6.4. Pacemaker
6.5. Ventricular Assist Device
6.6.1. Biventricular Assist Device
6.6.2. Left Ventricular Assist Device
6.6.3. Right Ventricular Assist Device
7. Congestive Heart Failure Treatment Device Market, by End-User
7.1. Introduction
7.2. Ambulatory Surgery Center
7.3. Hospitals & Clinics
8. Americas Congestive Heart Failure Treatment Device Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Congestive Heart Failure Treatment Device Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Congestive Heart Failure Treatment Device Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Abiomed, Inc.
12.1.1. Business Overview
12.1.2. Key Executives
12.1.3. Product & Services
12.2. Berlin Heart GmbH
12.2.1. Business Overview
12.2.2. Key Executives
12.2.3. Product & Services
12.3. Biotronik SE & Co. KG
12.3.1. Business Overview
12.3.2. Key Executives
12.3.3. Product & Services
12.4. Boston Scientific Corporation
12.4.1. Business Overview
12.4.2. Key Executives
12.4.3. Product & Services
12.5. HeartWare International, Inc.
12.5.1. Business Overview
12.5.2. Key Executives
12.5.3. Product & Services
12.6. Jarvik Heart, Inc.
12.6.1. Business Overview
12.6.2. Key Executives
12.6.3. Product & Services
12.7. LivaNova PLC
12.7.1. Business Overview
12.7.2. Key Executives
12.7.3. Product & Services
12.8. Medtronic plc
12.8.1. Business Overview
12.8.2. Key Executives
12.8.3. Product & Services
12.9. ReliantHeart Inc.
12.9.1. Business Overview
12.9.2. Key Executives
12.9.3. Product & Services
12.10. St. Jude Medical, Inc.
12.10.1. Business Overview
12.10.2. Key Executives
12.10.3. Product & Services
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing